US Patent

US11622941 — Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof

Formulation · Assigned to Impax Laboratories LLC · Expires 2034-10-07 · 8y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a specific oral solid formulation of levodopa and carbidopa that has a controlled release component and an immediate release component.

USPTO Abstract

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.

Drugs covered by this patent

Patent Metadata

Patent number
US11622941
Jurisdiction
US
Classification
Formulation
Expires
2034-10-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Impax Laboratories LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.